Marksans Pharma

{
  "main_header": {
    "sid": 604869,
    "name": "Marksans Pharma",
    "stock_name": "Marksans Pharma",
    "full_name": "Marksans Pharma Ltd",
    "name_url": "stocks-analysis/marksans-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "273.80",
    "chg": 4.75,
    "chgp": "1.77%",
    "dir": 1,
    "prev_price": "269.05",
    "mcapval": "12,147.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524404,
    "symbol": "MARKSANS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE750C01026",
    "curr_date": "Aug 07, 03:30 PM",
    "curr_time": "05:08 AM",
    "last_traded_at": "Aug 07, 03:30 PM IST",
    "bse_nse_vol": "10.75 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 07, 2026",
    "traded_date_str": "2026 08 07",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/marksans-pharma-604869-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Marksans Pharma Ltd is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/marksans-pharma-ltd-is-rated-buy-4142770",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/MarksansPharmaL_mojoScore_4142770.png",
        "date": "2026-08-08 10:10:40",
        "description": "Marksans Pharma Ltd is rated Buy by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 August 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Marksans Pharma Ltd is Rated Buy by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/marksans-pharma-ltd-is-rated-buy-by-marketsmojo-4142778",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/MarksansPharmaL_mojoScore_4142778.png",
        "date": "2026-08-08 10:10:40",
        "description": "Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Marksans Pharma Ltd Valuation Shifts Signal Heightened Price Attractiveness Amid Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-valuation-shifts-signal-heightened-price-attractiveness-amid-sector-dynamics-4134354",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/MarksansPharmaL_valuationdot_4134354.png",
        "date": "2026-08-04 08:00:57",
        "description": "Marksans Pharma Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a very expensive rating. This change, driven primarily by its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the stock’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Marksans Pharma Gains 4.87%: 3 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-gains-487-3-key-factors-driving-the-weeks-momentum-4131841",
        "imagepath": "",
        "date": "2026-08-01 16:12:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Jul:</strong> Stock surges 7.01% to Rs.263.50 on strong technical momentum</p>\n                    <p><strong>28 Jul:</strong> MarketsMOJO upgrades rating to Buy citing robust financials and technicals</p>\n                    <p><strong>29 Jul:</strong> Valuation grade shifts from very expensive to expensive amid sector comparisons</p>\n                    <p><strong>31 Jul:</strong> Week closes at Rs.258.25, up 4.87% for the week, outperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.246.25</div></div>\n                    <div class=\"st..."
      },
      {
        "title": "Marksans Pharma Ltd Valuation Shifts Signal Price Attractiveness Amid Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-valuation-shifts-signal-price-attractiveness-amid-sector-dynamics-4124996",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MarksansPharmaL_valuationdot_4124996.png",
        "date": "2026-07-29 08:01:09",
        "description": "Marksans Pharma Ltd has recently undergone a notable change in its valuation parameters, shifting from a very expensive to an expensive rating. This adjustment reflects evolving market perceptions and valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, which are critical for investors assessing the stock’s price attractiveness relative to its historical levels and sector peers."
      },
      {
        "title": "Marksans Pharma Upgraded to Buy on Strong Technicals and Financial Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/marksans-pharma-upgraded-to-buy-on-strong-technicals-and-financial-performance-4123656",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MarksansPharmaL_mojoScore_4123656.png",
        "date": "2026-07-28 08:44:26",
        "description": "Marksans Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements in technical indicators, robust financial trends, and a reassessment of valuation metrics. This upgrade, effective from 27 July 2026, is underpinned by a comprehensive analysis across four key parameters: Quality, Valuation, Financial Trend, and Technicals."
      },
      {
        "title": "Marksans Pharma Ltd Technical Momentum Shifts to Bullish Amid Strong Price Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-technical-momentum-shifts-to-bullish-amid-strong-price-gains-4123312",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MarksansPharmaL_technicaldot_4123312.png",
        "date": "2026-07-28 08:02:54",
        "description": "Marksans Pharma Ltd has demonstrated a significant shift in price momentum, supported by a series of bullish technical indicators and an upgraded Mojo Grade from Hold to Buy. The pharmaceutical company’s stock price surged 7.01% on 28 Jul 2026, closing at ₹263.50, signalling renewed investor confidence amid a broader positive technical outlook."
      },
      {
        "title": "Marksans Pharma Falls 7.81%: 5 Key Factors Behind the Sharp Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-falls-781-5-key-factors-behind-the-sharp-weekly-decline-4120960",
        "imagepath": "",
        "date": "2026-07-26 10:00:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>20 Jul:</strong> Stock opens at Rs.266.85, marginally down -0.09%</p>\n                    <p><strong>21 Jul:</strong> Sharp decline of 2.44% to Rs.260.35 on increased volume</p>\n                    <p><strong>22 Jul:</strong> Intraday low hit amid 7.47% drop and 6.09% gap down opening</p>\n                    <p><strong>23 Jul:</strong> Downgrade to Hold by MarketsMOJO; technical momentum shifts</p>\n                    <p><strong>24 Jul:</strong> Week closes at Rs.246.25, down 0.10% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.267.10</div></..."
      },
      {
        "title": "Marksans Pharma Downgraded to Hold Amid Mixed Technical and Valuation Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/marksans-pharma-downgraded-to-hold-amid-mixed-technical-and-valuation-signals-4117230",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/MarksansPharmaL_mojoScore_4117230.png",
        "date": "2026-07-23 08:26:41",
        "description": "Marksans Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 22 July 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite strong long-term returns and solid financials, recent technical shifts and valuation concerns have tempered enthusiasm among investors."
      }
    ],
    "total": 404,
    "sid": "604869",
    "stock_news_url": "https://www.marketsmojo.com/news/marksans-pharma-604869"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "06-Aug-2026",
      "details": "Please find attached newspaper publication for Annual General Meeting Notice",
      "source": "BSE"
    },
    {
      "caption": "Shareholders Annual General Meeting To Be Held On August 27 2026",
      "datetime": "04-Aug-2026",
      "details": "Notice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 2026",
      "source": "BSE"
    },
    {
      "caption": "Business Responsibility and Sustainability Reporting (BRSR)",
      "datetime": "04-Aug-2026",
      "details": "Please find enclosed the BRSR",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "12 Aug 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Marksans Pharma Ltd has declared <strong>90%</strong> dividend, ex-date: 20 Aug 26",
          "dt": "2026-08-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Marksans Pharma Ltd has announced <strong>1:10</strong> stock split, ex-date: 11 Mar 08",
          "dt": "2008-03-11",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Marksans Pharma Ltd is Rated Buy

2026-08-08 10:10:40

Marksans Pharma Ltd is rated Buy by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Marksans Pharma Ltd is Rated Buy by MarketsMOJO

2026-08-08 10:10:40

Marksans Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Marksans Pharma Ltd Valuation Shifts Signal Heightened Price Attractiveness Amid Sector Dynamics

2026-08-04 08:00:57

Marksans Pharma Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a very expensive rating. This change, driven primarily by its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the stock’s price attractiveness relative to its historical performance and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

Marksans Pharma Gains 4.87%: 3 Key Factors Driving the Week’s Momentum

2026-08-01 16:12:46

Key Events This Week

27 Jul: Stock surges 7.01% to Rs.263.50 on strong technical momentum

28 Jul: MarketsMOJO upgrades rating to Buy citing robust financials and technicals

29 Jul: Valuation grade shifts from very expensive to expensive amid sector comparisons

31 Jul: Week closes at Rs.258.25, up 4.87% for the week, outperforming Sensex

Week Open

Rs.246.25

Read full news article

Marksans Pharma Ltd Valuation Shifts Signal Price Attractiveness Amid Sector Dynamics

2026-07-29 08:01:09

Marksans Pharma Ltd has recently undergone a notable change in its valuation parameters, shifting from a very expensive to an expensive rating. This adjustment reflects evolving market perceptions and valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, which are critical for investors assessing the stock’s price attractiveness relative to its historical levels and sector peers.

Read full news article

Marksans Pharma Upgraded to Buy on Strong Technicals and Financial Performance

2026-07-28 08:44:26

Marksans Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements in technical indicators, robust financial trends, and a reassessment of valuation metrics. This upgrade, effective from 27 July 2026, is underpinned by a comprehensive analysis across four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Read full news article

Marksans Pharma Ltd Technical Momentum Shifts to Bullish Amid Strong Price Gains

2026-07-28 08:02:54

Marksans Pharma Ltd has demonstrated a significant shift in price momentum, supported by a series of bullish technical indicators and an upgraded Mojo Grade from Hold to Buy. The pharmaceutical company’s stock price surged 7.01% on 28 Jul 2026, closing at ₹263.50, signalling renewed investor confidence amid a broader positive technical outlook.

Read full news article

Marksans Pharma Falls 7.81%: 5 Key Factors Behind the Sharp Weekly Decline

2026-07-26 10:00:52

Key Events This Week

20 Jul: Stock opens at Rs.266.85, marginally down -0.09%

21 Jul: Sharp decline of 2.44% to Rs.260.35 on increased volume

22 Jul: Intraday low hit amid 7.47% drop and 6.09% gap down opening

23 Jul: Downgrade to Hold by MarketsMOJO; technical momentum shifts

24 Jul: Week closes at Rs.246.25, down 0.10% on the day

Week Open

Rs.267.10

Read full news article

Marksans Pharma Downgraded to Hold Amid Mixed Technical and Valuation Signals

2026-07-23 08:26:41

Marksans Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 22 July 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite strong long-term returns and solid financials, recent technical shifts and valuation concerns have tempered enthusiasm among investors.

Read full news article

View All News